<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2242">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943722</url>
  </required_header>
  <id_info>
    <org_study_id>V503-002</org_study_id>
    <secondary_id>2009_611</secondary_id>
    <secondary_id>2009-011617-25</secondary_id>
    <nct_id>NCT00943722</nct_id>
  </id_info>
  <brief_title>A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)</brief_title>
  <official_title>A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human&#xD;
      papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent&#xD;
      participants between 9 and 15 years old and demonstrate the consistency of the manufactured&#xD;
      vaccine through assessment of 3 different final manufacturing process lots of V503.&#xD;
&#xD;
      The primary hypotheses are as follows:&#xD;
&#xD;
        1. The 9-valent HPV L1 VLP vaccine when administered to preadolescent and adolescent boys&#xD;
           and girls 9 to 15 years of age and young women 16 to 26 years of age is generally&#xD;
           well-tolerated.&#xD;
&#xD;
        2. 9-valent HPV L1 VLP vaccine induces non-inferior immune responses in preadolescent and&#xD;
           adolescent girls 9 to 15 years of age who are seronegative at Day 1 to the relevant HPV&#xD;
           type compared to young women 16 to 26 years of age who are seronegative at Day 1 and&#xD;
           polymerase chain reaction (PCR)-negative Day 1 through Month 7 to the relevant HPV type,&#xD;
           as measured by anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 geometric mean titers&#xD;
           (GMTs) at 4 weeks post-dose 3.&#xD;
&#xD;
        3. The 9-valent HPV L1 VLP vaccine induces non-inferior immune responses in preadolescent&#xD;
           and adolescent boys 9 to 15 years of age who are seronegative at Day 1 to the relevant&#xD;
           HPV type compared to young women 16 to 26 years of age who are seronegative at Day 1 and&#xD;
           PCR-negative Day 1 through Month 7 to the relevant HPV type, as measured by anti-HPV 6,&#xD;
           11, 16, 18, 31, 33, 45, 52, and 58 GMTs at 4 weeks post-dose 3.&#xD;
&#xD;
        4. Three separate final manufacturing process (FMP) lots of the 9-valent HPV L1 VLP vaccine&#xD;
           induce similar immune responses, as measured by anti-HPV types 6, 11, 16, 18, 31, 33,&#xD;
           45, 52, and 58 GMTs at 4 weeks post-dose 3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The base study V503-002 was a 12-month study that collected immunogenicity data through Month&#xD;
      7 and safety data through Month 12.&#xD;
&#xD;
      An optional extension study (V503-002 EXT1) collected safety and immunogenicity information&#xD;
      through Month 36. Participants enrolled in the 16- to 26-year-old cohort in the base study&#xD;
      were not included in EXT1. Per protocol, EXT1 included immunogenicity data from a subset of&#xD;
      9- to 15-year-old females and safety data from all 9- to 15-year-old females regardless of&#xD;
      lot administered.&#xD;
&#xD;
      An optional second extension study (V503-002 EXT2) collected long-term safety and&#xD;
      immunogenicity information through approximately Month 126. No study vaccine was administered&#xD;
      in the extension studies. Participants enrolled in the 16- to 26-year-old cohort in the base&#xD;
      study were not included in EXT2. Per protocol, EXT2 included immunogenicity data from a&#xD;
      subset of 9- to 15-year-old females and effectiveness and safety data from all 9- to&#xD;
      15-year-old females regardless of lot administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2009</start_date>
  <completion_date type="Actual">April 22, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</measure>
    <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
    <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</measure>
    <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
    <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)</measure>
    <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
    <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With Systemic AEs</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. Systemic AEs were those not categorized as injection-site AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extension Study: GMTs For Each of the HPV Types Contained in the Vaccine</measure>
    <time_frame>Up to ~Month 126</time_frame>
    <description>Serum antibody titers (milli Merck Units/mL) measured by cLIA to each of the 9vHPV types were assessed. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine</measure>
    <time_frame>Up to ~Month 126</time_frame>
    <description>Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</measure>
    <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
    <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])</measure>
    <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
    <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)</measure>
    <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
    <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females</measure>
    <time_frame>Up to ~Month 126</time_frame>
    <description>Persistent infection is when a participant is positive by polymerase chain reaction (PCR) for the same HPV type in cervicovaginal/external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later. Per protocol, the extension study included 9- to 15-year-old females regardless of lot administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males</measure>
    <time_frame>Up to ~Month 126</time_frame>
    <description>Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females</measure>
    <time_frame>Up to ~Month 126</time_frame>
    <description>The combined incidence of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, and cervical/vulvar/vaginal cancers, related to HPV 6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males</measure>
    <time_frame>Up to ~Month 126</time_frame>
    <description>The combined incidence of penile intraepithelial neoplasia, penile/perineal/perianal cancers, and genital warts related to HPV6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. For each study participant, person-years follow up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events</measure>
    <time_frame>Up to ~Month 126</time_frame>
    <description>A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3074</enrollment>
  <condition>Cervical Cancers</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <condition>Genital Lesions</condition>
  <condition>PAP Test Abnormalities</condition>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>9- to 15-Year-Old Females (Lot 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9- to 15-Year-Old Females (Lot 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9- to 15-Year-Old Females (Lot 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9- to 15-Year-Old Males (Lot 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16- to 26-Year-Old Females (Lot 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V503</intervention_name>
    <description>Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.</description>
    <arm_group_label>16- to 26-Year-Old Females (Lot 1)</arm_group_label>
    <arm_group_label>9- to 15-Year-Old Females (Lot 1)</arm_group_label>
    <arm_group_label>9- to 15-Year-Old Females (Lot 2)</arm_group_label>
    <arm_group_label>9- to 15-Year-Old Females (Lot 3)</arm_group_label>
    <arm_group_label>9- to 15-Year-Old Males (Lot 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Boys and Girls Age 9 to 15:&#xD;
&#xD;
          -  Participant has not had sexual intercourse prior to the study and does not plan to&#xD;
             become sexually active during the study period Day 1 to Month 7&#xD;
&#xD;
        Women Age 16 to 26:&#xD;
&#xD;
          -  Participant has never had Pap testing or has had only normal results&#xD;
&#xD;
          -  Participant has had 0 to 4 sexual partners at the time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Boys and Girls Age 9 to 15:&#xD;
&#xD;
          -  History of allergic reaction that required medical intervention&#xD;
&#xD;
          -  Currently enrolled in any other clinical study&#xD;
&#xD;
          -  Participant is pregnant&#xD;
&#xD;
          -  Participant is immunocompromised or has taken immunosuppressants in the last year&#xD;
&#xD;
          -  Participant has received a marketed HPV vaccine or participated in an HPV vaccine&#xD;
             clinical trial&#xD;
&#xD;
          -  Participant has a history of positive test for HPV&#xD;
&#xD;
        Women Age 16 to 26:&#xD;
&#xD;
          -  History of allergic reaction that required medical intervention&#xD;
&#xD;
          -  Currently enrolled in any other clinical study&#xD;
&#xD;
          -  Participant is pregnant&#xD;
&#xD;
          -  Participant is immunocompromised or has taken immunosuppressants in the last year&#xD;
&#xD;
          -  Participant has received a marketed HPV vaccine or participated in an HPV vaccine&#xD;
             clinical trial&#xD;
&#xD;
          -  Participant has a history of positive test for HPV&#xD;
&#xD;
          -  Participant has a history of abnormal cervical biopsy result&#xD;
&#xD;
          -  Participant has a history of external genital lesions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme LLC</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Finland</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Luxembourg A, Moreira ED Jr, Samakoses R, Kim KH, Sun X, Maansson R, Moeller E, Christiano S, Chen J. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Hum Vaccin Immunother. 2015;11(6):1306-12. doi: 10.1080/21645515.2015.1009819.</citation>
    <PMID>26086587</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015 Jul;136(1):e28-39. doi: 10.1542/peds.2014-3745.</citation>
    <PMID>26101366</PMID>
  </results_reference>
  <results_reference>
    <citation>Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2). pii: e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15.</citation>
    <PMID>27422279</PMID>
  </results_reference>
  <results_reference>
    <citation>Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, Van Damme P, Moreira ED Jr, Ferris D, Block S, Bautista O, Gallagher N, McCauley J, Luxembourg A. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020 Dec;10:100203. doi: 10.1016/j.pvr.2020.100203. Epub 2020 Jul 11.</citation>
    <PMID>32659510</PMID>
  </results_reference>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <results_first_submitted>December 12, 2014</results_first_submitted>
  <results_first_submitted_qc>January 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2015</results_first_posted>
  <last_update_submitted>April 15, 2022</last_update_submitted>
  <last_update_submitted_qc>April 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT00943722/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The base study was a 12-month study that collected immunogenicity data through Month 7 and safety data through Month 12.</recruitment_details>
      <pre_assignment_details>Extension study 1 (EXT1) collected data to Month 36. Extension study 2 (EXT2) collected long-term data through ~Month 126. No study vaccine was administered.&#xD;
Per protocol, participants enrolled in the 16- to 26-year-old arm in the base study were not included in the extension study.&#xD;
Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered (arm: &quot;Extension Study: 9- to 15- Year Old Females&quot;).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 1)</title>
          <description>9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="P2">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 2)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 2.</description>
        </group>
        <group group_id="P3">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 3)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 3.</description>
        </group>
        <group group_id="P4">
          <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="P5">
          <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="P6">
          <title>Extension Study: 9- to 15-Year-Old Females</title>
          <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
        </group>
        <group group_id="P7">
          <title>Extension Study: 9- to 15-Year-Old Males</title>
          <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="648"/>
                <participants group_id="P2" count="643"/>
                <participants group_id="P3" count="644"/>
                <participants group_id="P4" count="669"/>
                <participants group_id="P5" count="470"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="646"/>
                <participants group_id="P2" count="642"/>
                <participants group_id="P3" count="644"/>
                <participants group_id="P4" count="666"/>
                <participants group_id="P5" count="468"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="637"/>
                <participants group_id="P2" count="633"/>
                <participants group_id="P3" count="638"/>
                <participants group_id="P4" count="658"/>
                <participants group_id="P5" count="462"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="635"/>
                <participants group_id="P2" count="627"/>
                <participants group_id="P3" count="637"/>
                <participants group_id="P4" count="653"/>
                <participants group_id="P5" count="455"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>At Least One Dose With Protocol-specified Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="643"/>
                <participants group_id="P2" count="639"/>
                <participants group_id="P3" count="641"/>
                <participants group_id="P4" count="662"/>
                <participants group_id="P5" count="466"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="623"/>
                <participants group_id="P2" count="621"/>
                <participants group_id="P3" count="631"/>
                <participants group_id="P4" count="647"/>
                <participants group_id="P5" count="444"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Month 12 visit not completed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>First Extension Study: EXT 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1604"/>
                <participants group_id="P7" count="568"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1489"/>
                <participants group_id="P7" count="527"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="115"/>
                <participants group_id="P7" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="38"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="32"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disposition Unknown</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="44"/>
                <participants group_id="P7" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Extension Study: EXT 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="971"/>
                <participants group_id="P7" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="720"/>
                <participants group_id="P7" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="251"/>
                <participants group_id="P7" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="111"/>
                <participants group_id="P7" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="137"/>
                <participants group_id="P7" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per protocol, baseline characteristics were analyzed in all participants randomized in the base study.</population>
      <group_list>
        <group group_id="B1">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 1)</title>
          <description>9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="B2">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 2)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 2.</description>
        </group>
        <group group_id="B3">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 3)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 3.</description>
        </group>
        <group group_id="B4">
          <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="B5">
          <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="648"/>
            <count group_id="B2" value="643"/>
            <count group_id="B3" value="644"/>
            <count group_id="B4" value="669"/>
            <count group_id="B5" value="470"/>
            <count group_id="B6" value="3074"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>9 to 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="440"/>
                    <measurement group_id="B2" value="432"/>
                    <measurement group_id="B3" value="432"/>
                    <measurement group_id="B4" value="450"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 to 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="219"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 to 26 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="470"/>
                    <measurement group_id="B6" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="648"/>
                    <measurement group_id="B2" value="643"/>
                    <measurement group_id="B3" value="644"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="470"/>
                    <measurement group_id="B6" value="2405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="669"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</title>
        <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.</description>
        <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
        <population>9-15-year-old females and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
        <group_list>
          <group group_id="O1">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 1)</title>
            <description>9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</title>
          <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.</description>
          <population>9-15-year-old females and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1715.4" lower_limit="1595.1" upper_limit="1844.7"/>
                    <measurement group_id="O2" value="900.8" lower_limit="822.3" upper_limit="986.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1295.1" lower_limit="1204.1" upper_limit="1393.0"/>
                    <measurement group_id="O2" value="706.6" lower_limit="645.2" upper_limit="773.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="529"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6979.8" lower_limit="6508.1" upper_limit="7485.8"/>
                    <measurement group_id="O2" value="3522.6" lower_limit="3223.5" upper_limit="3849.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2153.7" lower_limit="1980.4" upper_limit="2342.1"/>
                    <measurement group_id="O2" value="882.7" lower_limit="795.4" upper_limit="979.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="522"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1891.6" lower_limit="1745.7" upper_limit="2049.7"/>
                    <measurement group_id="O2" value="753.9" lower_limit="682.5" upper_limit="832.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="980.4" lower_limit="911.7" upper_limit="1054.3"/>
                    <measurement group_id="O2" value="466.8" lower_limit="426.9" upper_limit="510.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="368"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="714.4" lower_limit="651.9" upper_limit="782.8"/>
                    <measurement group_id="O2" value="272.2" lower_limit="243.8" upper_limit="303.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="533"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="932.9" lower_limit="864.8" upper_limit="1006.4"/>
                    <measurement group_id="O2" value="419.6" lower_limit="381.4" upper_limit="461.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1286.7" lower_limit="1195.7" upper_limit="1384.6"/>
                    <measurement group_id="O2" value="590.5" lower_limit="538.2" upper_limit="647.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% confidence interval (CI) of GMT ratio be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.63</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.13</ci_lower_limit>
            <ci_upper_limit>2.80</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.21</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.87</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.27</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.97</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</title>
        <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.</description>
        <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
        <population>9-15-year-old males and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
        <group_list>
          <group group_id="O1">
            <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</title>
          <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.</description>
          <population>9-15-year-old males and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="559"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2084.7" lower_limit="1944.0" upper_limit="2235.7"/>
                    <measurement group_id="O2" value="900.8" lower_limit="822.3" upper_limit="986.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="559"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1487.1" lower_limit="1386.5" upper_limit="1595.0"/>
                    <measurement group_id="O2" value="706.6" lower_limit="645.2" upper_limit="773.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8628.9" lower_limit="8065.9" upper_limit="9231.3"/>
                    <measurement group_id="O2" value="3522.6" lower_limit="3223.5" upper_limit="3849.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2822.8" lower_limit="2602.8" upper_limit="3061.5"/>
                    <measurement group_id="O2" value="882.7" lower_limit="795.4" upper_limit="979.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="564"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2221.2" lower_limit="2056.1" upper_limit="2399.5"/>
                    <measurement group_id="O2" value="753.9" lower_limit="682.5" upper_limit="832.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                    <count group_id="O2" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1198.7" lower_limit="1117.1" upper_limit="1286.2"/>
                    <measurement group_id="O2" value="466.8" lower_limit="426.9" upper_limit="510.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="368"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="907.0" lower_limit="830.2" upper_limit="991.0"/>
                    <measurement group_id="O2" value="272.2" lower_limit="243.8" upper_limit="303.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1037.8" lower_limit="964.4" upper_limit="1116.9"/>
                    <measurement group_id="O2" value="419.6" lower_limit="381.4" upper_limit="461.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1567.7" lower_limit="1460.2" upper_limit="1683.1"/>
                    <measurement group_id="O2" value="590.5" lower_limit="538.2" upper_limit="647.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.88</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>3.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.80</ci_lower_limit>
            <ci_upper_limit>3.65</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.60</ci_lower_limit>
            <ci_upper_limit>3.34</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.29</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>3.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.89</ci_lower_limit>
            <ci_upper_limit>3.84</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>non-inferiority requires that the lower bound of two-sided 95% CI of GMT ratio be greater than 0.67</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group</p_value_desc>
            <method>ANOVA</method>
            <method_desc>model with a response of log individual titers and a fixed effect for comparison group</method_desc>
            <param_type>GMT ratio</param_type>
            <param_value>2.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.37</ci_lower_limit>
            <ci_upper_limit>2.98</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)</title>
        <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.</description>
        <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
        <population>9-15-year-old females who received 3 vaccinations from Lots 1, 2, or 3 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
        <group_list>
          <group group_id="O1">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 1)</title>
            <description>9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 2)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 2.</description>
          </group>
          <group group_id="O3">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 3)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)</title>
          <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.</description>
          <population>9-15-year-old females who received 3 vaccinations from Lots 1, 2, or 3 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="549"/>
                <count group_id="O3" value="565"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="536"/>
                    <count group_id="O3" value="544"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1715.4" lower_limit="1588.7" upper_limit="1852.2"/>
                    <measurement group_id="O2" value="1763.3" lower_limit="1635.4" upper_limit="1901.3"/>
                    <measurement group_id="O3" value="1659.9" lower_limit="1540.3" upper_limit="1788.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="536"/>
                    <count group_id="O3" value="544"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1295.1" lower_limit="1197.8" upper_limit="1400.3"/>
                    <measurement group_id="O2" value="1311.7" lower_limit="1214.9" upper_limit="1416.3"/>
                    <measurement group_id="O3" value="1232.0" lower_limit="1141.7" upper_limit="1329.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="529"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="556"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6979.8" lower_limit="6476.1" upper_limit="7522.8"/>
                    <measurement group_id="O2" value="7292.9" lower_limit="6772.7" upper_limit="7853.1"/>
                    <measurement group_id="O3" value="6948.2" lower_limit="6458.7" upper_limit="7474.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="547"/>
                    <count group_id="O3" value="563"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2153.7" lower_limit="1970.9" upper_limit="2353.5"/>
                    <measurement group_id="O2" value="2134.1" lower_limit="1955.6" upper_limit="2329.0"/>
                    <measurement group_id="O3" value="1966.6" lower_limit="1804.3" upper_limit="2143.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="522"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1891.6" lower_limit="1738.5" upper_limit="2058.2"/>
                    <measurement group_id="O2" value="1867.8" lower_limit="1719.3" upper_limit="2029.1"/>
                    <measurement group_id="O3" value="1879.0" lower_limit="1731.0" upper_limit="2039.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="543"/>
                    <count group_id="O3" value="560"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="980.4" lower_limit="909.2" upper_limit="1057.2"/>
                    <measurement group_id="O2" value="922.7" lower_limit="856.2" upper_limit="994.4"/>
                    <measurement group_id="O3" value="931.1" lower_limit="865.0" upper_limit="1002.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="548"/>
                    <count group_id="O3" value="565"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="714.4" lower_limit="650.1" upper_limit="785.0"/>
                    <measurement group_id="O2" value="827.7" lower_limit="754.1" upper_limit="908.5"/>
                    <measurement group_id="O3" value="678.4" lower_limit="619.0" upper_limit="743.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="533"/>
                    <count group_id="O2" value="547"/>
                    <count group_id="O3" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="932.9" lower_limit="860.8" upper_limit="1011.0"/>
                    <measurement group_id="O2" value="1007.9" lower_limit="931.0" upper_limit="1091.2"/>
                    <measurement group_id="O3" value="971.2" lower_limit="898.1" upper_limit="1050.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="539"/>
                    <count group_id="O3" value="560"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1286.7" lower_limit="1190.0" upper_limit="1391.3"/>
                    <measurement group_id="O2" value="1344.9" lower_limit="1244.6" upper_limit="1453.3"/>
                    <measurement group_id="O3" value="1208.1" lower_limit="1119.6" upper_limit="1303.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0).</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the ratio of the GMTs be entirely contained within the interval (0.5, 2.0)</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.</description>
        <time_frame>Up to 5 days after any vaccination</time_frame>
        <population>All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.</population>
        <group_list>
          <group group_id="O1">
            <title>9- to 15-Year-Old Females (Lots 1, 2 or 3)</title>
            <description>9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O3">
            <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.</description>
          <population>All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1923"/>
                <count group_id="O2" value="662"/>
                <count group_id="O3" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9"/>
                    <measurement group_id="O2" value="72.8"/>
                    <measurement group_id="O3" value="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With Systemic AEs</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. Systemic AEs were those not categorized as injection-site AEs.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.</population>
        <group_list>
          <group group_id="O1">
            <title>9- to 15-Year-Old Females (Lots 1, 2 or 3)</title>
            <description>9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O3">
            <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With Systemic AEs</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. Systemic AEs were those not categorized as injection-site AEs.</description>
          <population>All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1923"/>
                <count group_id="O2" value="662"/>
                <count group_id="O3" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="41.8"/>
                    <measurement group_id="O3" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)</title>
        <description>Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.</description>
        <time_frame>Up to 5 days after any vaccination</time_frame>
        <population>All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.</population>
        <group_list>
          <group group_id="O1">
            <title>9- to 15-Year-Old Females (Lots 1, 2, or 3)</title>
            <description>Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O3">
            <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)</title>
          <description>Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.</description>
          <population>All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1908"/>
                <count group_id="O2" value="660"/>
                <count group_id="O3" value="463"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</title>
        <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
        <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
        <population>9-15-year-old females and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
        <group_list>
          <group group_id="O1">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 1)</title>
            <description>9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])</title>
          <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
          <population>9-15-year-old females and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6 cLIA ≥30 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.9" upper_limit="100"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11 cLIA ≥16 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16 cLIA ≥20 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="529"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18 cLIA ≥24 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31 cLIA ≥10 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="522"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="368"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="533"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])</title>
        <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
        <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
        <population>9-15-year-old males and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range</population>
        <group_list>
          <group group_id="O1">
            <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])</title>
          <description>Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
          <population>9-15-year-old males and 16-26-year-old females who received 3 vaccinations from Lot 1 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6 cLIA ≥30 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="559"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11 cLIA ≥16 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="559"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16 cLIA ≥20 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18 cLIA ≥24 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31 cLIA ≥10 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="564"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="567"/>
                    <count group_id="O2" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="368"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority is demonstrated if the lower limit of the 95% CI for the percentage point difference is greater than -5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)</title>
        <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
        <time_frame>4 weeks post-vaccination 3 (Month 7)</time_frame>
        <population>9- to 15-year-old females who received 3 vaccinations from Lots 1, 2, and 3 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range</population>
        <group_list>
          <group group_id="O1">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 1)</title>
            <description>9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 2)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 2.</description>
          </group>
          <group group_id="O3">
            <title>Base Study: 9- to 15-Year-Old Females (Lot 3)</title>
            <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)</title>
          <description>Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.</description>
          <population>9- to 15-year-old females who received 3 vaccinations from Lots 1, 2, and 3 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="549"/>
                <count group_id="O3" value="565"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6 cLIA ≥30 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="536"/>
                    <count group_id="O3" value="544"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.8" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.3" lower_limit="98.1" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 11 cLIA ≥16 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="517"/>
                    <count group_id="O2" value="536"/>
                    <count group_id="O3" value="544"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 16 cLIA ≥20 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="529"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="556"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 18 cLIA ≥24 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="547"/>
                    <count group_id="O3" value="563"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 31 cLIA ≥10 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="522"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.8" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 33 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="543"/>
                    <count group_id="O3" value="560"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 45 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="534"/>
                    <count group_id="O2" value="548"/>
                    <count group_id="O3" value="565"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 52 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="533"/>
                    <count group_id="O2" value="547"/>
                    <count group_id="O3" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 58 cLIA ≥8 mMU/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="539"/>
                    <count group_id="O3" value="560"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).</non_inferiority_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extension Study: GMTs For Each of the HPV Types Contained in the Vaccine</title>
        <description>Serum antibody titers (milli Merck Units/mL) measured by cLIA to each of the 9vHPV types were assessed. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
        <time_frame>Up to ~Month 126</time_frame>
        <population>All participants who met the following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: 9- to 15-Year-Old Females</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: 9- to 15-Year-Old Males</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2)</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: GMTs For Each of the HPV Types Contained in the Vaccine</title>
          <description>Serum antibody titers (milli Merck Units/mL) measured by cLIA to each of the 9vHPV types were assessed. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
          <population>All participants who met the following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="341"/>
                    <count group_id="O2" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.3" lower_limit="111.1" upper_limit="134.7"/>
                    <measurement group_id="O2" value="129.5" lower_limit="112.5" upper_limit="149.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" lower_limit="72.5" upper_limit="88.8"/>
                    <measurement group_id="O2" value="91.0" lower_limit="78.4" upper_limit="105.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.0" lower_limit="357.3" upper_limit="454.5"/>
                    <measurement group_id="O2" value="414.3" lower_limit="353.8" upper_limit="485.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.1" lower_limit="116.7" upper_limit="140.7"/>
                    <measurement group_id="O2" value="148.4" lower_limit="130.2" upper_limit="169.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="343"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.9" lower_limit="97.6" upper_limit="121.6"/>
                    <measurement group_id="O2" value="128.6" lower_limit="111.2" upper_limit="148.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="53.7" upper_limit="65.2"/>
                    <measurement group_id="O2" value="69.6" lower_limit="60.7" upper_limit="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="37.7" upper_limit="47.1"/>
                    <measurement group_id="O2" value="49.8" lower_limit="43.0" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="50.5" upper_limit="60.6"/>
                    <measurement group_id="O2" value="59.6" lower_limit="52.0" upper_limit="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="69.2" upper_limit="84.6"/>
                    <measurement group_id="O2" value="90.5" lower_limit="78.4" upper_limit="104.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine</title>
        <description>Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
        <time_frame>Up to ~Month 126</time_frame>
        <population>All participants who met the following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: 9- to 15-Year-Old Females</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: 9- to 15-Year-Old Males</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2)</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine</title>
          <description>Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
          <population>All participants who met the following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="341"/>
                    <count group_id="O2" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" lower_limit="78.3" upper_limit="86.6"/>
                    <measurement group_id="O2" value="84.1" lower_limit="77.8" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="81.0" upper_limit="88.9"/>
                    <measurement group_id="O2" value="87.0" lower_limit="81.0" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="95.0" upper_limit="98.8"/>
                    <measurement group_id="O2" value="98.3" lower_limit="95.0" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="75.5" upper_limit="84.2"/>
                    <measurement group_id="O2" value="83.7" lower_limit="77.4" upper_limit="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="343"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="86.4" upper_limit="93.0"/>
                    <measurement group_id="O2" value="92.7" lower_limit="87.8" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="81.0" upper_limit="88.8"/>
                    <measurement group_id="O2" value="89.3" lower_limit="83.8" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="77.2" upper_limit="85.9"/>
                    <measurement group_id="O2" value="92.3" lower_limit="87.2" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="84.4" upper_limit="91.4"/>
                    <measurement group_id="O2" value="89.2" lower_limit="83.7" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="94.0" upper_limit="98.2"/>
                    <measurement group_id="O2" value="97.1" lower_limit="93.5" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females</title>
        <description>Persistent infection is when a participant is positive by polymerase chain reaction (PCR) for the same HPV type in cervicovaginal/external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later. Per protocol, the extension study included 9- to 15-year-old females regardless of lot administered.</description>
        <time_frame>Up to ~Month 126</time_frame>
        <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11 HPV11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: 9- to 15-Year-Old Females</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females</title>
          <description>Persistent infection is when a participant is positive by polymerase chain reaction (PCR) for the same HPV type in cervicovaginal/external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later. Per protocol, the extension study included 9- to 15-year-old females regardless of lot administered.</description>
          <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11 HPV11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
          <units>Cases per 10,000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="33.6" lower_limit="33.6" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males</title>
        <description>Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.</description>
        <time_frame>Up to ~Month 126</time_frame>
        <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: 9- to 15-Year-Old Males</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males</title>
          <description>Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.</description>
          <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
          <units>Cases per 10,000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" spread="21.9" lower_limit="21.9" upper_limit="112.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females</title>
        <description>The combined incidence of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, and cervical/vulvar/vaginal cancers, related to HPV 6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
        <time_frame>Up to ~Month 126</time_frame>
        <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: 9- to 15-Year-Old Females</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females</title>
          <description>The combined incidence of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, and cervical/vulvar/vaginal cancers, related to HPV 6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
          <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
          <units>Cases per 10,000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="866"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.1" lower_limit="0.1" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males</title>
        <description>The combined incidence of penile intraepithelial neoplasia, penile/perineal/perianal cancers, and genital warts related to HPV6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. For each study participant, person-years follow up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later.</description>
        <time_frame>Up to ~Month 126</time_frame>
        <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: 9- to 15-Year-Old Males</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males</title>
          <description>The combined incidence of penile intraepithelial neoplasia, penile/perineal/perianal cancers, and genital warts related to HPV6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. For each study participant, person-years follow up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later.</description>
          <population>The per-protocol effectiveness population, which included participants who were seronegative (by cLIA) to the relevant HPV type(s) at Day 1 (seronegative to both HPV 6 and 11 for analysis of HPV 6 and 11-related endpoints), received all 3 doses of 9vHPV vaccine with the correct dose of the clinical material within 1 year, and had no other protocol violation that could interfere with evaluation of vaccine effectiveness.</population>
          <units>Cases per 10,000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0" lower_limit="0.0" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events</title>
        <description>A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
        <time_frame>Up to ~Month 126</time_frame>
        <population>All participants who received at least 1 study vaccination in the base study and had follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: 9- to 15-Year-Old Females</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: 9- to 15-Year-Old Males</title>
            <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2)</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events</title>
          <description>A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.</description>
          <population>All participants who received at least 1 study vaccination in the base study and had follow-up data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Base Study: Up to ~12 months; Extension Study: Up to ~126 months</time_frame>
      <desc>Base Study and Extension Study: ACM was analyzed in all randomized participants. Safety was analyzed in all participants who received at least one dose of 9vHPV and had available follow-up data, per protocol. ACM and safety were reported separately for base study, first extension (EXT1) and second extension (EXT2).</desc>
      <group_list>
        <group group_id="E1">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 1)</title>
          <description>9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="E2">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 2)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 2.</description>
        </group>
        <group group_id="E3">
          <title>Base Study: 9- to 15-Year-Old Females (Lot 3)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 3.</description>
        </group>
        <group group_id="E4">
          <title>Base Study: 9- to 15-Year-Old Males (Lot 1)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="E5">
          <title>Base Study: 16- to 26-Year-Old Females (Lot 1)</title>
          <description>9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.</description>
        </group>
        <group group_id="E6">
          <title>EXT1: 9- to 15-Year-Old Females</title>
          <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension study, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1).</description>
        </group>
        <group group_id="E7">
          <title>EXT1: 9- to 15-Year-Old Males</title>
          <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension study, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1).</description>
        </group>
        <group group_id="E8">
          <title>EXT2: 9- to 15-Year-Old Females</title>
          <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension study, the participants were followed up for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
        </group>
        <group group_id="E9">
          <title>EXT2: 9- to 15-Year-Old Males</title>
          <description>In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension study, the participants were followed up for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="648"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1604"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="971"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="641"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="662"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="466"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1604"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="971"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="643"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cervical incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="643"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="643"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="641"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="538" subjects_at_risk="643"/>
                <counts group_id="E2" subjects_affected="537" subjects_at_risk="639"/>
                <counts group_id="E3" subjects_affected="554" subjects_at_risk="641"/>
                <counts group_id="E4" subjects_affected="505" subjects_at_risk="662"/>
                <counts group_id="E5" subjects_affected="404" subjects_at_risk="466"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="264" subjects_affected="184" subjects_at_risk="643"/>
                <counts group_id="E2" events="287" subjects_affected="192" subjects_at_risk="639"/>
                <counts group_id="E3" events="281" subjects_affected="195" subjects_at_risk="641"/>
                <counts group_id="E4" events="219" subjects_affected="159" subjects_at_risk="662"/>
                <counts group_id="E5" events="220" subjects_affected="132" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1166" subjects_affected="506" subjects_at_risk="643"/>
                <counts group_id="E2" events="1183" subjects_affected="513" subjects_at_risk="639"/>
                <counts group_id="E3" events="1215" subjects_affected="529" subjects_at_risk="641"/>
                <counts group_id="E4" events="919" subjects_affected="465" subjects_at_risk="662"/>
                <counts group_id="E5" events="970" subjects_affected="393" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="317" subjects_affected="207" subjects_at_risk="643"/>
                <counts group_id="E2" events="372" subjects_affected="237" subjects_at_risk="639"/>
                <counts group_id="E3" events="380" subjects_affected="226" subjects_at_risk="641"/>
                <counts group_id="E4" events="249" subjects_affected="173" subjects_at_risk="662"/>
                <counts group_id="E5" events="261" subjects_affected="150" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="91" subjects_affected="76" subjects_at_risk="643"/>
                <counts group_id="E2" events="67" subjects_affected="57" subjects_at_risk="639"/>
                <counts group_id="E3" events="74" subjects_affected="64" subjects_at_risk="641"/>
                <counts group_id="E4" events="94" subjects_affected="84" subjects_at_risk="662"/>
                <counts group_id="E5" events="53" subjects_affected="43" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="182" subjects_affected="120" subjects_at_risk="643"/>
                <counts group_id="E2" events="170" subjects_affected="122" subjects_at_risk="639"/>
                <counts group_id="E3" events="156" subjects_affected="113" subjects_at_risk="641"/>
                <counts group_id="E4" events="143" subjects_affected="98" subjects_at_risk="662"/>
                <counts group_id="E5" events="166" subjects_affected="106" subjects_at_risk="466"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1604"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="568"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="971"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

